A reimbursement on the cost to purchase and use FebriDx could...

A reimbursement on the cost to purchase and use FebriDx could boost sales of FebriDx very quickly.....and what if the PLA reimbursement comes in as expected any day now (as per above linked post).?

Then we may see an increase in uptake of Febridx, however until that occurs, it doesn't matter. The numbers I estimated would remain.

A reimbursement on the cost to purchase and use FebriDx could boost sales of FebriDx very quickly. Im over now talking about if buts and maybes. The wording from the company was "robust sales" which translated to $300,000. Until it happens, means jack all now.

Also, the CLIA waiver grant includes another approx US $5 million dollars which i believe LDX will work to pick up within the next 12 months.

The additional funds for the CLIA study aren't relevant for the next 12 months and this is to extend the label to under 12's. You need to understand that if the funds don't increase in the next 12 months, they are relying on another capital raise, or they go bust now. So $5M of Government funds for a specific study is only relevant if the company is still active at that point. And even at that point, if still active, what is the share price likely to sit at with bugger all growth over the next 12 months.

Working/Liquid capital is what keeps this afloat. Not unobligated funds from the Government for a specific study. We cant use the $5M on anything other than the study.


FYI - Look at the recent announcement from AT1 about their HIV Tests. Key example of what I am talking about with LDX. Material announcement about orders = 10% gain in the share price. Also provides evidence of uptake of the tests.

LDX is unwilling to do this because of "ramping".